Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.34 |
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.32 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17712267 | 1.00 | CYP3A4 (0.34) | CYP3A4CYP2C9TMPRSS2BTN3A1 | |
| SCHEMBL22143082 | 1.00 | CYP3A4 (0.34) | CYP3A4CYP2C9TMPRSS2BTN3A1 | |
| SCHEMBL17712268 | 1.00 | CYP3A4 (0.34) | CYP3A4CYP2C9TMPRSS2BTN3A1 | |
| SCHEMBL26878466 | 1.00 | CYP3A4 (0.34) | CYP3A4CYP2C9TMPRSS2BTN3A1 | |
| SCHEMBL17712270 | 1.00 | CYP3A4 (0.34) | CYP3A4CYP2C9TMPRSS2BTN3A1 | |
| SCHEMBL23034488 | 1.00 | CYP3A4 (0.34) | CYP3A4CYP2C9TMPRSS2BTN3A1 | |
| SCHEMBL25013580 | 0.95 | TMPRSS2 (0.32) | TMPRSS2 | |
| SCHEMBL25519234 | 0.94 | CYP3A4 (0.34) | CYP3A4CYP2C9TMPRSS2BTN3A1 | |
| SCHEMBL25013991 | 0.93 | TMPRSS2 (0.32) | TMPRSS2 | |
| SCHEMBL30269833 | 0.92 | TMPRSS2 (0.30) | TMPRSS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219993-A1 | ANTIVIRAL APPLICATION OF NUCLEOSIDE ANALOG OR COMBINATION FORMULATION CONTAINING NUCLEOSIDE ANALOG | VIGONVITA LIFE SCIENCES CO., LTD. (CN) | 2023-07-13 | — | — | US | disclosed |
| WO-2023102472-A1 | ANTIVIRAL PRODRUGS AND FORMULATIONS THEREOF | THE SCRIPPS RESEARCH INSTITUTE (US) | 2023-06-08 | — | — | WO | disclosed |
| US-11344565-B2 | Methods for the preparation of ribosides | GILEAD SCIENCES, INC. (US) | 2022-05-31 | — | — | US | disclosed |
| US-11266666-B2 | Methods for treating Filoviridae virus infections | GILEAD SCIENCES, INC. (US) | 2022-03-08 | — | — | US | disclosed |
| EP-3785717-B1 | METHODS FOR TREATING CORONAVIRIDAE INFECTIONS | GILEAD SCIENCES INC (US) | 2022-01-05 | — | — | EP | disclosed |
| EP-3212175-B1 | METHODS FOR THE PREPARATION OF RIBOSIDES | GILEAD SCIENCES INC (US) | 2021-11-24 | — | — | EP | disclosed |
| US-20210309689-A1 | METHODS OF PREPARING 1'-CYANO NUCLEOSIDES | GILEAD SCIENCES, INC. | 2021-10-07 | — | — | US | disclosed |
| US-11007208-B2 | Methods for treating arenaviridae and coronaviridae virus infections | GILEAD SCIENCES, INC. (US) | 2021-05-18 | — | — | US | disclosed |
| US-20200352967-A1 | METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2020-11-12 | — | — | US | disclosed |
| US-10695357-B2 | Methods for treating filoviridae virus infections | GILEAD SCIENCES, INC. (US) | 2020-06-30 | — | — | US | disclosed |
| US-10695361-B2 | Methods for treating arenaviridae and coronaviridae virus infections | GILEAD SCIENCES, INC. (US) | 2020-06-30 | — | — | US | disclosed |
| US-20200197422-A1 | METHODS FOR THE PREPARATION OF RIBOSIDES | GILEAD SCIENCES, INC. | 2020-06-25 | — | — | US | disclosed |
| US-20190275063-A1 | METHODS FOR TREATING FILOVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2019-09-12 | — | — | US | disclosed |
| US-20190255085-A1 | METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2019-08-22 | — | — | US | disclosed |
| US-10251898-B2 | Methods for treating Filoviridae virus infections | GILEAD SCIENCES, INC. (US) | 2019-04-09 | — | — | US | disclosed |
| US-10251904-B2 | Methods for treating arenaviridae and coronaviridae virus infections | GILEAD SCIENCES, INC. (US) | 2019-04-09 | — | — | US | disclosed |
| EP-3212174-B1 | METHODS FOR TREATING FILOVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES INC (US) | 2018-05-16 | — | — | EP | disclosed |
| US-9949994-B2 | Methods for treating Filoviridae virus infections | GILEAD SCIENCES, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| WO-2017184668-A1 | METHODS FOR TREATING FLAVIVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. (US) | 2017-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10251904-B2 | Methods for treating arenaviridae and coronaviridae virus infections | ACE, PNP, ACE2 | CYP3A4 1145/4885CYP2C9 2167/4885TMPRSS2 12/4885 |
| US-20190275063-A1 | METHODS FOR TREATING FILOVIRIDAE VIRUS INFECTIONS | PNP, PRPF4, RPIA | CYP3A4 772/4885CYP2C9 2974/4885TMPRSS2 1951/4885 |
| US-10695361-B2 | Methods for treating arenaviridae and coronaviridae virus infections | ACE, PNP, ACE2 | CYP3A4 1145/4885CYP2C9 2167/4885TMPRSS2 12/4885 |
| US-11007208-B2 | Methods for treating arenaviridae and coronaviridae virus infections | ACE, PNP, ACE2 | CYP3A4 1145/4885CYP2C9 2167/4885TMPRSS2 12/4885 |
| US-11344565-B2 | Methods for the preparation of ribosides | RUVBL2, RUVBL1, EIF2AK2 | CYP3A4 2996/4885CYP2C9 4188/4885TMPRSS2 3973/4885 |
| US-20190255085-A1 | METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE VIRUS INFECTIONS | ACE, PNP, ACE2 | CYP3A4 1145/4885CYP2C9 2167/4885TMPRSS2 12/4885 |
| US-10695357-B2 | Methods for treating filoviridae virus infections | PNP, PRPF4, RPIA | CYP3A4 772/4885CYP2C9 2974/4885TMPRSS2 1951/4885 |
| US-10251898-B2 | Methods for treating Filoviridae virus infections | PNP, PRPF4, RPIA | CYP3A4 772/4885CYP2C9 2974/4885TMPRSS2 1951/4885 |
| US-20200352967-A1 | METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE VIRUS INFECTIONS | ACE, PNP, ACE2 | CYP3A4 1145/4885CYP2C9 2167/4885TMPRSS2 12/4885 |
| US-20230219993-A1 | ANTIVIRAL APPLICATION OF NUCLEOSIDE ANALOG OR COMBINATION FORMULATION CONTAINING NUCLEOSIDE ANALOG | PNP, TYMP, PIGS | CYP3A4 888/4885CYP2C9 1258/4885TMPRSS2 145/4885 |
| US-20200197422-A1 | METHODS FOR THE PREPARATION OF RIBOSIDES | PRPS1, PRPF4, PRPF31 | CYP3A4 2895/4885CYP2C9 4593/4885TMPRSS2 3100/4885 |
| US-20210309689-A1 | METHODS OF PREPARING 1'-CYANO NUCLEOSIDES | PNP, TYMP, DUT | CYP3A4 981/4885CYP2C9 358/4885TMPRSS2 4740/4885 |
| US-11266666-B2 | Methods for treating Filoviridae virus infections | PNP, PRPF4, RPIA | CYP3A4 772/4885CYP2C9 2974/4885TMPRSS2 1951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.